AUB ScholarWorks

Apoptosis induction by Epican Forte in HTLV-1 positive and negative malignant T-cells

Show simple item record Harakeh S. Diab-Assaf M. Niedzwiecki A. Khalife J. Abu-El-Ardat K. Rath M.
dc.contributor.editor 2006 2017-10-03T15:43:36Z 2017-10-03T15:43:36Z 2006
dc.identifier 10.1016/j.leukres.2005.11.027
dc.identifier.issn 01452126
dc.description.abstract The effects of a novel nutrient formulation Epican Forte (EF) were evaluated on proliferation and induction of apoptosis using non-cytotoxic concentrations against HTLV-1 positive (HuT-102 andamp; C91-PL) and negative (CEM andamp; Jurkat) cells. EF showed anti-proliferative effect as determined by MTT assay and TGF mRNA protein expression using RT-PCR. EF resulted in the down-regulation of TGF-α and an up-regulation in TGF-β2. EF caused a significant increase in apoptotic cells in the preG1 phase. These results were confirmed using Cell Death ELISA and Annexin V-FITC. Induction of apoptosis was caused by an up-regulation of p53, p21 and Bax protein levels and a down-regulation of Bcl-2α protein expression level. © 2005 Elsevier Ltd. All rights reserved.
dc.format.extent Pages: (869-881)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Leukemia Research; Publication Year: 2006; Volume: 30; no. 7; Pages: (869-881);
dc.source Scopus
dc.title Apoptosis induction by Epican Forte in HTLV-1 positive and negative malignant T-cells
dc.type Article
dc.contributor.affiliation Harakeh, S., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Diab-Assaf, M., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Niedzwiecki, A., Dr. Rath Research Institute, Santa Clara, CA, United States
dc.contributor.affiliation Khalife, J., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Abu-El-Ardat, K., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Rath, M., Dr. Rath Research Institute, Santa Clara, CA, United States
dc.contributor.authorAddress Harakeh, S.; Department of Biology, American University of Beirut, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut; Faculty: Faculty of Arts and Sciences; Department: Biology;
dc.contributor.authorDepartment Biology
dc.contributor.faculty Faculty of Arts and Sciences
dc.contributor.authorInitials Harakeh, S
dc.contributor.authorInitials Diab-Assaf, M
dc.contributor.authorInitials Niedzwiecki, A
dc.contributor.authorInitials Khalife, J
dc.contributor.authorInitials Abu-El-Ardat, K
dc.contributor.authorInitials Rath, M
dc.contributor.authorReprintAddress Harakeh, S (reprint author), Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
dc.contributor.authorResearcherID Harakeh, Steve-K-5709-2012
dc.contributor.authorUniversity American University of Beirut
dc.description.cited Agarwal A, 2004, AM J PATHOL, V164, P1683, DOI 10.1016-S0002-9440(10)63727-3; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006-abbi.2000.1742; Ahn WS, 2003, DNA CELL BIOL, V22, P217, DOI 10.1089-104454903321655846; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056-NEJM199901143400204; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172-JCI6863; Cascinu S, 2000, CANCER INVEST, V18, P411, DOI 10.3109-07357900009032811; Chen JJ, 2004, BJU INT, V93, P1082, DOI 10.1111-1464-410X.2004.04785.x; CHUBINSKAYA SG, 1989, VOP MED KHIM, V35, P30; Cooke JP, 1997, ANNU REV MED, V48, P489; Dong Y, 2003, CANCER RES, V63, P52; Dunker N, 2002, GASTROENTEROLOGY, V122, P1364, DOI 10.1053-gast.2002.32991; Fleming J, 2001, NUTR CANCER, V40, P42, DOI 10.1207-S15327914NC401_9; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002-1097-0142(196504)18:4522::AID-CNCR28201804183.0.CO;2-J; Gansauge S, 1998, CELL GROWTH DIFFER, V9, P611; Gopee NV, 2004, TOXICOL SCI, V78, P204, DOI 10.1093-toxsci-ktb072; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007-s002800050788; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016-S0003-9861(02)00668-9; Harakeh S, 2004, CHEM-BIOL INTERACT, V148, P101, DOI 10.1016-j.cbi.2004.05.002; Harakeh S, 1995, NUTRITION, V11, P684; HARAKEH S, 1990, P NATL ACAD SCI USA, V87, P7245, DOI 10.1073-pnas.87.18.7245; Harakeh S, 1997, AIDS RES HUM RETROV, V13, P235, DOI 10.1089-aid.1997.13.235; HARAKEH S, 1994, CHEM-BIOL INTERACT, V91, P207, DOI 10.1016-0009-2797(94)90041-8; HARAKEH S, 1991, AM J CLIN NUTR, V54, pS1231; Harakeh Steve, 1994, Journal of Nutritional Medicine, V4, P393, DOI 10.3109-13590849409003588; Hare Y, 2001, GREEN TEA HLTH BENEF; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006-bbrc.2001.5293; Holt PR, 1998, JAMA-J AM MED ASSOC, V280, P1074, DOI 10.1001-jama.280.12.1074; Ip C, 2001, ANTICANCER RES, V21, P863; Jamison JM, 2004, BIOCHEM PHARMACOL, V67, P337, DOI 10.1016-j.bcp.2003.08.040; Kampman E, 2000, CANCER CAUSE CONTROL, V11, P459, DOI 10.1023-A:1008914108739; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053-gast.2001.25544; Kawakami K, 2004, CLIN CANCER RES, V10, P5264, DOI 10.1158-1078-0432.CCR-04-0314; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084-jem.163.5.1037; Kinscherf R, 1998, FASEB J, V12, P461; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159-000068711; Li HC, 2000, JPN J CANCER RES, V91, P34; Liu MJ, 2005, CANCER CHEMOTH PHARM, V55, P79, DOI 10.1007-s00280-004-0849-3; Maramag C, 1997, PROSTATE, V32, P188, DOI 10.1002-(SICI)1097-0045(19970801)32:3188::AID-PROS53.0.CO;2-H; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182-blood-2002-01-0151; Morini M, 1999, INT J BIOL MARKER, V14, P268; MORTENSEON MM, 1986, J SURG RES, V114, P302; OKAZAKI I, 1992, J LAB CLIN MED, V120, P908; Ostrakhovitch EA, 2004, ARCH BIOCHEM BIOPHYS, V423, P351, DOI; Rath M, 1992, ORTHOMOL MED, V7, P17; RATH M, 1991, J ORTHOMOL MED, V7, P17; Reddy VG, 2001, BIOCHEM BIOPH RES CO, V282, P409, DOI 10.1006-bbrc.2001.4593; Roomi MW, 2005, IN VIVO, V19, P179; Roomi MW, 2005, BREAST CANCER RES, V7, pR291, DOI 10.1186-bcr989; ROOMI MW, 2005, ONCOL REP, V12, P421; Roomi MW, 2005, MED ONCOL, V22, P129, DOI 10.1385-MO:22:2:129; Roomi MW, 2005, ONCOL REP, V13, P253; ROOMI MW, 2003, CANC OVERVIEW CELL M; Roomi MW, 2004, JANA, V7, P40; ROY M, 2003, MUTAT RES, V524, P33; SIMEONE AM, 2002, MOL CANCER THER, V1, P1366; Slattery ML, 1999, AM J EPIDEMIOL, V150, P869; Sun ZY, 2002, BBA-PROTEIN STRUCT M, V1596, P182, DOI 10.1016-S0167-4838(02)00233-9; Swede H, 2003, CANCER EPIDEM BIOMAR, V12, P1248; TOSETTI F, 2002, FASEB J, V16, P12; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074-jbc.274.37.26321; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007-BF00918135; Wolf Federica I., 1999, Frontiers in Bioscience, V4, pd607, DOI 10.2741-Wolf; Wu K, 2002, J NATL CANCER I, V94, P437, DOI 10.1093-jnci-94.6.437; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074-jbc.M101143200; Zhong WX, 2001, CANCER RES, V61, P7071
dc.description.citedCount 16
dc.description.citedTotWOSCount 16
dc.description.citedWOSCount 16
dc.format.extentCount 13
dc.identifier.coden LERED
dc.identifier.pubmedID 16427125
dc.identifier.scopusID 33744526743
dc.relation.ispartOfISOAbbr Leuk. Res.
dc.relation.ispartOfIssue 7
dc.relation.ispartofPubTitle Leukemia Research
dc.relation.ispartofPubTitleAbbr Leuk. Res.
dc.relation.ispartOfVolume 30
dc.source.ID WOS:000238787600014
dc.type.publication Journal
dc.subject.otherAuthKeyword Amino acids
dc.subject.otherAuthKeyword Antioxidants
dc.subject.otherAuthKeyword Apoptosis
dc.subject.otherAuthKeyword Ascorbic acid (AA)
dc.subject.otherAuthKeyword Epican Forte
dc.subject.otherAuthKeyword Epigallocatechin-3-gallate (EGCG)
dc.subject.otherAuthKeyword HTLV-1
dc.subject.otherAuthKeyword Leukemia
dc.subject.otherChemCAS 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide, 298-93-1
dc.subject.otherChemCAS fluorescein isothiocyanate, 25168-13-2, 27072-45-3, 3326-32-7
dc.subject.otherChemCAS lipocortin 5, 111237-10-6
dc.subject.otherChemCAS protein bcl 2, 219306-68-0
dc.subject.otherChemCAS protein p21, 85306-28-1
dc.subject.otherChemCAS transforming growth factor, 76057-06-2
dc.subject.otherChemCAS Acetylcysteine, 616-91-1
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS Arginine, 74-79-3
dc.subject.otherChemCAS Ascorbic Acid, 50-81-7
dc.subject.otherChemCAS Catechin, 154-23-4
dc.subject.otherChemCAS Copper, 7440-50-8
dc.subject.otherChemCAS DNA, 9007-49-2
dc.subject.otherChemCAS epigallocatechin gallate, 989-51-5
dc.subject.otherChemCAS Lysine, 56-87-1
dc.subject.otherChemCAS Manganese, 7439-96-5
dc.subject.otherChemCAS Proline, 147-85-3
dc.subject.otherChemCAS Selenium, 7782-49-2
dc.subject.otherChemCAS Transforming Growth Factors, 76057-06-2
dc.subject.otherIndex 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex epican forte
dc.subject.otherIndex fluorescein isothiocyanate
dc.subject.otherIndex lipocortin 5
dc.subject.otherIndex messenger RNA
dc.subject.otherIndex protein Bax
dc.subject.otherIndex protein bcl 2
dc.subject.otherIndex protein p21
dc.subject.otherIndex protein p53
dc.subject.otherIndex transforming growth factor
dc.subject.otherIndex transforming growth factor alpha
dc.subject.otherIndex transforming growth factor beta2
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex apoptosis
dc.subject.otherIndex article
dc.subject.otherIndex cancer cell culture
dc.subject.otherIndex cell cycle G1 phase
dc.subject.otherIndex cell death
dc.subject.otherIndex cell proliferation
dc.subject.otherIndex controlled study
dc.subject.otherIndex down regulation
dc.subject.otherIndex drug effect
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex enzyme linked immunosorbent assay
dc.subject.otherIndex human
dc.subject.otherIndex human cell
dc.subject.otherIndex Human T cell leukemia virus 1
dc.subject.otherIndex priority journal
dc.subject.otherIndex protein expression
dc.subject.otherIndex reverse transcription polymerase chain reaction
dc.subject.otherIndex statistical significance
dc.subject.otherIndex T lymphocyte
dc.subject.otherIndex upregulation
dc.subject.otherIndex Acetylcysteine
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Apoptosis
dc.subject.otherIndex Arginine
dc.subject.otherIndex Ascorbic Acid
dc.subject.otherIndex Catechin
dc.subject.otherIndex Cell Cycle
dc.subject.otherIndex Cell Line, Tumor
dc.subject.otherIndex Cell Proliferation
dc.subject.otherIndex Copper
dc.subject.otherIndex Dietary Supplements
dc.subject.otherIndex DNA
dc.subject.otherIndex Dose-Response Relationship, Drug
dc.subject.otherIndex Drug Screening Assays, Antitumor
dc.subject.otherIndex Enzyme-Linked Immunosorbent Assay
dc.subject.otherIndex Flow Cytometry
dc.subject.otherIndex Gene Expression Profiling
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Lysine
dc.subject.otherIndex Manganese
dc.subject.otherIndex Proline
dc.subject.otherIndex Reverse Transcriptase Polymerase Chain Reaction
dc.subject.otherIndex Selenium
dc.subject.otherIndex Sensitivity and Specificity
dc.subject.otherIndex Structure-Activity Relationship
dc.subject.otherIndex T-Lymphocytes
dc.subject.otherIndex Transforming Growth Factors
dc.subject.otherKeywordPlus GREEN TEA EXTRACT
dc.subject.otherKeywordPlus NF-KAPPA-B
dc.subject.otherKeywordPlus HUMAN-IMMUNODEFICIENCY-VIRUS
dc.subject.otherKeywordPlus PROSTATE-CANCER CELLS
dc.subject.otherKeywordPlus GROWTH-FACTOR-BETA
dc.subject.otherKeywordPlus CYCLE ARREST
dc.subject.otherKeywordPlus ASCORBIC-ACID
dc.subject.otherKeywordPlus IN-VITRO
dc.subject.otherKeywordPlus BREAST-CANCER
dc.subject.otherKeywordPlus COLON-CANCER
dc.subject.otherWOS Oncology
dc.subject.otherWOS Hematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account